Le Lézard
Classified in: Health
Subjects: PDT, WOM

Women's Health Company, Kindbody, Enters Los Angeles Market with Mobile Fertility Pop-Up


LOS ANGELES, Dec. 10, 2018 /PRNewswire/ -- Kindbody, a new women's healthcare company, enters the Los Angeles market this week with its mobile fertility pop-up. Kindbody, led by former Founder/CEO of Progyny, Gina Bartasi, is building a national network of boutique women's healthcare facilities through pop-up and brick-and-mortar locations, with technology and patient experience at its core.

An Instagram post announcing Kindbody's LA debut

Kindbody will offer complimentary fertility hormone tests and consultations in two Los Angeles locations on two consecutive days this week. On December 12th, the fertility pop-up will be at 573 West 8th Street, between South Grand Avenue and Olive Street, from 9 am to 6 pm. On December 13th, the fertility pop-up will be at 700 South Spaulding Street, at Wilshire Boulevard, from 9 am and 6 pm.

Kindbody promoted the mobile fertility pop-up to a LA audience on Instagram in the weeks leading up to the event days and received 2,000 pre-sign-ups. They confirmed appointment slots for 400 attendees, and will try to accommodate as many walk-ins as possible.

Kindbody has already held mobile fertility pop-ups in Manhattan, the Hamptons, Palo Alto, and San Francisco. At the pop-ups, they do a blood test for AMH levels, which is a hormone associated with ovarian reserve. Kindbody has performed almost 1,000 AMH tests to date, and found that 20% of all patients tested had a score under 1, indicating a low ovarian reserve. Around 50% of patients with a score under 1 were under the age of 35. Kindbody provides on-site consultations with physicians to contextualize the information and answer any questions.  

"To truly improve outcomes and experience, we know the discussion about women's health must start earlier and with their gynecologist," said Founding Physician, Dr. Fahimeh Sasan, who joined Kindbody after a decade at Mount Sinai. "Kindbody's mission is to democratize care, start the conversation earlier, and make it easier for patients to get the care they need."

Kindbody recently announced the hire of Dr. Lynn Westphal from Stanford University School of Medicine as their Chief Medical Officer, Reproductive Endocrinology. "This is an opportunity to raise the overall quality of care," said Dr. Westphal. "People stay away from the medical system when they feel like it isn't designed for them. Women want to be listened to, and they want to be treated as a whole person. Kindbody's approach is the way medicine should be moving."

About Kindbody:
Kindbody is reinventing women's healthcare for the modern woman, starting with fertility and wellness services. We are building boutique locations from the ground up, bringing together clinical excellence, best-in-class technology, and accessible pricing, connecting the full patient experience in one, intuitive solution. Visit www.kindbody.com and follow us on InstagramTwitter, and Facebook.

Media Inquiries:
Rebecca Silver, Senior Director of Marketing
[email protected]
(609) 947-0793

(PRNewsfoto/Kindbody)

SOURCE Kindbody


These press releases may also interest you

at 22:16
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...



News published on and distributed by: